Research ArticleDrug Discovery and Translational Medicine
BI 1002494, a Novel Potent and Selective Oral Spleen Tyrosine Kinase Inhibitor, Displays Differential Potency in Human Basophils and B Cells
David J. Lamb, Stefan Lutz Wollin, Andreas Schnapp, Daniel Bischoff, Klaus J. Erb, Thierry Bouyssou, Bernd Guilliard, Christine Strasser, Eva Wex, Sylvia Blum, Eva Thaler, Helga Nickel, Oliver Radmacher, Hannah Haas, Jennifer L. Swantek, Don Souza, Melissa Canfield, Della White, Mark Panzenbeck, Mohammed A. Kashem, Mary Sanville-Ross, Takeshi Kono, Katherina Sewald, Armin Braun, Helena Obernolte, Olga Danov, Gerhard Schaenzle, Georg Rast, Gerd-Michael Maier and Matthias Hoffmann
Journal of Pharmacology and Experimental Therapeutics June 2016, 357 (3) 554-561; DOI: https://doi.org/10.1124/jpet.116.233155
David J. Lamb
Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
Stefan Lutz Wollin
Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
Andreas Schnapp
Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
Daniel Bischoff
Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
Klaus J. Erb
Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
Thierry Bouyssou
Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
Bernd Guilliard
Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
Christine Strasser
Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
Eva Wex
Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
Sylvia Blum
Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
Eva Thaler
Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
Helga Nickel
Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
Oliver Radmacher
Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
Hannah Haas
Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
Jennifer L. Swantek
Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
Don Souza
Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
Melissa Canfield
Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
Della White
Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
Mark Panzenbeck
Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
Mohammed A. Kashem
Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
Mary Sanville-Ross
Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
Takeshi Kono
Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
Katherina Sewald
Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
Armin Braun
Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
Helena Obernolte
Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
Olga Danov
Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
Gerhard Schaenzle
Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
Georg Rast
Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
Gerd-Michael Maier
Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
Matthias Hoffmann
Immunology and Respiratory Research (D.J.L., S.L.W., A.S., K.J.E., T.B., B.G., C.S., E.W., S.B., E.T., H.N., O.R., H.H.), Discovery Drug Support (D.B., G.S., G.R., G.-M.M.), and Medicinal Chemistry (M.H.), Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany; Immunology and Respiratory Research (J.L.S., D.S., M.C., D.W., M.P.) and Small Molecule Discovery Research (M.A.K., M.S.-R.), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut; Kobe Pharma Research Institute, Nippon Boehringer Ingelheim Co., Chuo-ku, Kobe City, Japan (T.K.); and Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany (K.S., A.B., H.O., O.D.)
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleDrug Discovery and Translational Medicine
SYK Inhibitor with Differential Cellular Pharmacology
David J. Lamb, Stefan Lutz Wollin, Andreas Schnapp, Daniel Bischoff, Klaus J. Erb, Thierry Bouyssou, Bernd Guilliard, Christine Strasser, Eva Wex, Sylvia Blum, Eva Thaler, Helga Nickel, Oliver Radmacher, Hannah Haas, Jennifer L. Swantek, Don Souza, Melissa Canfield, Della White, Mark Panzenbeck, Mohammed A. Kashem, Mary Sanville-Ross, Takeshi Kono, Katherina Sewald, Armin Braun, Helena Obernolte, Olga Danov, Gerhard Schaenzle, Georg Rast, Gerd-Michael Maier and Matthias Hoffmann
Journal of Pharmacology and Experimental Therapeutics June 1, 2016, 357 (3) 554-561; DOI: https://doi.org/10.1124/jpet.116.233155
Research ArticleDrug Discovery and Translational Medicine
SYK Inhibitor with Differential Cellular Pharmacology
David J. Lamb, Stefan Lutz Wollin, Andreas Schnapp, Daniel Bischoff, Klaus J. Erb, Thierry Bouyssou, Bernd Guilliard, Christine Strasser, Eva Wex, Sylvia Blum, Eva Thaler, Helga Nickel, Oliver Radmacher, Hannah Haas, Jennifer L. Swantek, Don Souza, Melissa Canfield, Della White, Mark Panzenbeck, Mohammed A. Kashem, Mary Sanville-Ross, Takeshi Kono, Katherina Sewald, Armin Braun, Helena Obernolte, Olga Danov, Gerhard Schaenzle, Georg Rast, Gerd-Michael Maier and Matthias Hoffmann
Journal of Pharmacology and Experimental Therapeutics June 1, 2016, 357 (3) 554-561; DOI: https://doi.org/10.1124/jpet.116.233155
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement